spironolactone has been researched along with ST Elevated Myocardial Infarction in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 2,854 patients with STEMI with early coronary revascularization participating in the randomized EPHESUS (Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial were analyzed." | 2.82 | Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHESUS Trial). ( Agrinier, N; Camenzind, E; Fay, R; Girerd, N; Pitt, B; Popovic, B; Rossignol, P; Zannad, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, JP | 1 |
| Duarte, K | 1 |
| Montalescot, G | 2 |
| Pitt, B | 3 |
| de Sa, EL | 1 |
| Hamm, CW | 2 |
| Flather, M | 2 |
| Verheugt, F | 1 |
| Shi, H | 1 |
| Turgonyi, E | 1 |
| Orri, M | 1 |
| Rossignol, P | 2 |
| Vincent, J | 1 |
| Zannad, F | 3 |
| Beygui, F | 1 |
| Van Belle, E | 1 |
| Ecollan, P | 1 |
| Machecourt, J | 1 |
| Lopez De Sa, E | 1 |
| Verheugt, FWA | 1 |
| Vicaut, E | 1 |
| Bulluck, H | 1 |
| Fröhlich, GM | 1 |
| Nicholas, JM | 1 |
| Mohdnazri, S | 1 |
| Gamma, R | 1 |
| Davies, J | 1 |
| Sirker, A | 1 |
| Mathur, A | 1 |
| Blackman, D | 1 |
| Garg, P | 1 |
| Moon, JC | 1 |
| Greenwood, JP | 1 |
| Hausenloy, DJ | 1 |
| Popovic, B | 1 |
| Girerd, N | 1 |
| Agrinier, N | 1 |
| Camenzind, E | 1 |
| Fay, R | 1 |
1 review available for spironolactone and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.
Topics: Aged; Canrenoic Acid; Eplerenone; Equivalence Trials as Topic; Female; Humans; Male; Middle Aged; Mi | 2018 |
3 trials available for spironolactone and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Linear Models; Logistic Models; M | 2018 |
Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
Topics: Aged; Canrenoic Acid; Cardiac Imaging Techniques; Double-Blind Method; Female; Humans; Magnetic Reso | 2019 |
Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHESUS Trial).
Topics: Aged; Cause of Death; Double-Blind Method; Electrocardiography; Eplerenone; Female; Follow-Up Studie | 2016 |